PDF(Pubmed)
Abstract：
OBJECTIVE: To report first clinical use of novel medical treatment for Acanthamoeba keratitis.
METHODS: Interventional observational case series. Two patients with Acanthamoeba keratitis were unsuccessfully treated with polihexanide (PHMB) 0.02% and propamidine 0.1% for 6 weeks, then all were shifted in a compassionate use of PHMB 0.08% with novel standardized protocol. The postinterventional follow-up of patients was at least 7 months.
RESULTS: PHMB 0.08% eyedrops in a novel standardized protocol improved infection resolution and led to complete healing of the lesion after 4 weeks in the two cases. Corneal opacities and neovascularization decreased slowly, best-corrected visual acuity slightly improved and progressively increased in the further 7 months, and no infection recurrence occurred.
CONCLUSIONS: This preliminary report of two cases shows promising response to polihexanide 0.08% lowering drastically the illness duration, with reduced chance of recurrence, and mostly improving patients\' quality of life.
METHODS: Interventional observational case series. Two patients with Acanthamoeba keratitis were unsuccessfully treated with polihexanide (PHMB) 0.02% and propamidine 0.1% for 6 weeks, then all were shifted in a compassionate use of PHMB 0.08% with novel standardized protocol. The postinterventional follow-up of patients was at least 7 months.
RESULTS: PHMB 0.08% eyedrops in a novel standardized protocol improved infection resolution and led to complete healing of the lesion after 4 weeks in the two cases. Corneal opacities and neovascularization decreased slowly, best-corrected visual acuity slightly improved and progressively increased in the further 7 months, and no infection recurrence occurred.
CONCLUSIONS: This preliminary report of two cases shows promising response to polihexanide 0.08% lowering drastically the illness duration, with reduced chance of recurrence, and mostly improving patients\' quality of life.
摘要：
目的：首次报道新型药物治疗棘阿米巴角膜炎的临床应用。
方法：介入观察病例系列。两名棘阿米巴角膜炎患者未成功接受0.02%的polihexanide（PHMB）和0.1%的propamidine治疗6周，然后,所有人都在新的标准化方案中同情地使用PHMB0.08%.患者介入后随访至少7个月。
结果：PHMB0.08%滴眼液在一种新的标准化方案中提高了感染消退率，并导致2例患者在4周后病灶完全愈合。角膜混浊和新生血管缓慢减少，最佳矫正视力略有改善，并在进一步的7个月内逐渐增加，无感染复发。
结论：这份对两个病例的初步报告显示，脊髓灰质炎对0.08%的反应有希望，可显著降低病程，减少复发的机会，主要改善患者的生活质量。
方法：介入观察病例系列。两名棘阿米巴角膜炎患者未成功接受0.02%的polihexanide（PHMB）和0.1%的propamidine治疗6周，然后,所有人都在新的标准化方案中同情地使用PHMB0.08%.患者介入后随访至少7个月。
结果：PHMB0.08%滴眼液在一种新的标准化方案中提高了感染消退率，并导致2例患者在4周后病灶完全愈合。角膜混浊和新生血管缓慢减少，最佳矫正视力略有改善，并在进一步的7个月内逐渐增加，无感染复发。
结论：这份对两个病例的初步报告显示，脊髓灰质炎对0.08%的反应有希望，可显著降低病程，减少复发的机会，主要改善患者的生活质量。
